Metabolic dysregulation in melanoma: Cause or consequence?

Cancer Discovery

Volumn 4, Issue 4, 2014, Pages 390-391

  Haq, Rizwan ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; B RAF KINASE INHIBITOR; DEOXYGLUCOSE; DICHLOROACETIC ACID; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR 1 ALPHA INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE DEHYDROGENASE KINASE INHIBITOR; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ARTICLE; CELL PROLIFERATION; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; LACTIC ACIDOSIS; MELANOMA; METABOLIC DISORDER; METASTATIC MELANOMA; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS;

GLYCOLYSIS; HUMANS; MELANOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84897937661     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-0173     Document Type: Article

References (10)

1. Balch CM, Gershenwald JE, Soong S-J, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
3. Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell 2013; 23: 302-15.
4. Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, et al. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov 2014;4:423-33.
5. Kim J-W, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3: 177-85.
6. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006; 3: 187-97.
7. Cairns RA, Papandreou I, Sutphin PD, Denko NC. Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proc Natl Acad Sci U S A 2007; 104: 9445-50.
8. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2010; 2: 31-4.
9. Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 2013; 24: 213-28.
10. Zheng B, Jeong JH, Asara JM, Yuan Y-Y, Granter SR, Chin L, et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 2009; 33: 237-47.